E
Ernexa Therapeutics Inc. ERNA
$0.2056 $0.00763.84% NASDAQ
Recommendation
Prev Close
$0.198
Volume
47,564
Avg Vol (90D)
7,232,777
Market Cap
$10.34M
Dividend & Yield
--
52-Week Range
$0.1506 - $2.63
P/E (TTM)
--
EPS (TTM)
-$7.32
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Ernexa Therapeutics Presented Promising Data on Innovative Cell Therapy Treatment at AACR Annual Meeting 2025
4/29/2025 - Globe Newswire
Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025
4/22/2025 - Globe Newswire
Eterna Therapeutics Inc. (NASDAQ:ERNA) Short Interest Down 42.8% in March
4/18/2025 - Ticker Report
Ernexa Therapeutics Closes New Funding Round
4/3/2025 - Globe Newswire
Eterna Therapeutics Changes Name to Ernexa Therapeutics to Reflect New Strategic Focus on ...
3/25/2025 - GuruFocus
Eterna Therapeutics Changes Name to Ernexa Therapeutics to Reflect New Strategic Focus on Ovarian Cancer and Autoimmune Disease
3/25/2025 - Globe Newswire
Eterna Therapeutics Hosts Successful Inaugural Meeting with Newly Formed Scientific Advisory ...
2/26/2025 - GuruFocus
Eterna Therapeutics Hosts Successful Inaugural Meeting with Newly Formed Scientific Advisory Board to Advance Cell Therapy Pipeline
2/26/2025 - Globe Newswire
Eterna Therapeutics Announces Expansion of Scientific Advisory Board
1/28/2025 - GuruFocus
Eterna Therapeutics Announces Expansion of Scientific Advisory Board
1/28/2025 - Globe Newswire
Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in ...
1/14/2025 - GuruFocus
Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian Cancer
1/14/2025 - Globe Newswire
Eterna Therapeutics Announces Appointment of Dr. Elena Ratner to Board of Directors
1/9/2025 - GuruFocus
Eterna Therapeutics Announces Appointment of Dr. Elena Ratner to Board of Directors
1/9/2025 - Globe Newswire
Eterna Therapeutics Launches Research to Evaluate its Lead Induced Mesenchymal Stem Cell Therapy Candidate's (ERNA-101) Ability to Induce and Modulate Antitumor Immunity in Ovarian Cancer and Breast Cancer Models
12/3/2024 - Globe Newswire
Eterna Therapeutics Announces Up to $1 Million Stock Repurchase Program
11/25/2024 - GuruFocus
Eterna Therapeutics Announces Up to $1 Million Stock Repurchase Program
11/25/2024 - Globe Newswire
Reviewing China Dongsheng International (OTCMKTS:CDSG) and Eterna Therapeutics (NASDAQ:ERNA)
11/22/2024 - Ticker Report
Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing
11/14/2024 - Globe Newswire
Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success
10/30/2024 - Globe Newswire
Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases
10/17/2024 - Globe Newswire
Short Interest in Eterna Therapeutics Inc. (NASDAQ:ERNA) Expands By 10.2%
10/1/2024 - Ticker Report
Eterna Therapeutics Strikes Key Deal for Disease-Fighting Tech
9/27/2024 - TipRanks Financial Blog
Eterna Therapeutics Inc. (NASDAQ:ERNA) Sees Large Drop in Short Interest
9/19/2024 - Ticker Report
Income Statement
Total Revenue (TTM)
$582.00K
EBITDA (TTM)
-$17.11M
EBIT (TTM)
-$17.25M
Net Income (TTM)
-$44.54M
Balance Sheet
Total Assets (Q)
$5.27M
Total Debt (Q)
$684.00K
Total Liabilities (Q)
$3.57M
Book Value Per Share (Q)
$0.0331
Cash Flow
Cash from Operations (TTM)
-$15.84M
Cash from Investing (TTM)
-$365.00K
Cash from Financing (TTM)
$6.26M
Net Change in Cash (TTM)
-$9.94M
Filings
Filing Date
Wednesday, March 12, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 12 and 16 (est)
Price History
Loading...
Beta
1.72
7-Day Total Return
-4.81%
30-Day Total Return
-20.92%
60-Day Total Return
-38.77%
90-Day Total Return
-16.22%
Year to Date Total Return
-44.28%
1-Year Total Return
-88.32%
2-Year Total Return
-93.37%
3-Year Total Return
-98.89%
5-Year Total Return
--
52-week Low
Apr 04, 2025 - $0.1506
52-week High
Jul 17, 2024 - $2.63
Valuation
Market Cap
$10.34M - Nano Cap
Enterprise Value
$9.30M
Price/Sales (TTM)
13.11
Price/Book (Q)
5.98
Dividends and Shares
Shares Outstanding
38.36M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.ernexatx.com
Phone Number
212 582 1199
Address
1035 Cambridge Street
Cambridge, MA 02141
Country
United States
Year Founded
2018
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company’s... more
NASDAQ 05/06/2025 3:20PM Eastern Quotes delayed